Baize Medical (02609.HK) Hot Stock Analysis - December 30, 2025

This analysis covers information on Hong Kong stock hot stocks released on December 30, 2025 (UTC+8), with core transaction data as of 14:08 HKT on December 29, 2025.

This analysis is based on public sources including Jinling Analysis Database [0], HKEX [1], AASTOCKS [2-4], Baize Medical Interim Report [5], and Tiger Securities [6]. Baize Medical (02609.HK) became a hot topic in Hong Kong stocks due to management changes (Lv Chao appointed as President) and hitting a 52-week low, but the company’s continuous losses, high price-to-sales ratio, and institutional selling activities have triggered negative market sentiment. Investors need to pay attention to its trading risks and long-term prospects.

Baize Medical (02609.HK) belongs to the Medical and Medical Beauty Services segment of the Healthcare industry [0], with a current market capitalization of approximately HK$5.41B [0]. Since its listing on June 23, 2025, the share price has continued to decline by 31.7% from the IPO day’s highest price of HK$6.02, hitting a 52-week low of HK$4.110 as of December 29, 2025 [1].

• Management Change Catalyst
  : On December 29, 2025, the company announced that Mr. Lv Chao was appointed as President and Mr. Jiang Zheng resigned as Assistant President, triggering market expectations for strategic adjustments [2].
• 52-Week Low Attraction
  : The stock price fell to an all-time low, attracting attention from bottom-fishing investors [1].

• On December 29, 2025, the trading volume was 3.13 million shares with a turnover of HK$12.92 million, which was comparable to the average level of the past month [1].
• The recent resistance level is approximately HK$4.200, and the support level is the current 52-week low of HK$4.110 [1].

• Negative sentiment dominates: Continuous stock price decline combined with the company’s loss status has led to insufficient market confidence.
• Short-selling activities: As of 12:25 on December 30, 2025, the short-selling ratio was 0.373% with a short-selling amount of HK$113,400 [3].
• Institutional selling: Green Economy (01315.HK) sold all its investor shares of Baize Medical on December 8, 2025, involving 2.7486 million shares with a total consideration of HK$30.2 million [4].

1. Uncertainty from Management Changes
   : The new president may promote strategic adjustments, but there is no clear direction in the short term, and market sentiment is still suppressed by the loss status [2].
2. Contradiction Between Low Price and Risk
   : The 52-week low attracts speculative investors, but the company reported a loss of RMB 20.3 million in the first half of 2025 [5], and the price-to-sales ratio remains as high as 4.14 [6], so valuation pressure has not been relieved.
3. Significance of Institutional Behavior
   : Green Economy’s full-scale sell-off and current short-selling activities reflect institutions’ doubts about the company’s short-term value [3-4].

• Continuous Loss Pressure
  : The interim report shows that the company is still in a loss state [5].
• High Valuation Risk
  : The price-to-sales ratio of 4.14 is relatively high compared to peer companies in the same industry [6].
• Short-selling and Institutional Selling Risks
  : Short-term short-selling activities and institutional reductions exacerbate stock price volatility [3-4].

• Technical Support Formation
  : The 52-week low forms short-term support [1].
• New Management Potential
  : The new president may bring opportunities for strategic optimization [2].

• High priority: Loss situation, valuation pressure, institutional selling.
• Medium priority: Management strategic adjustment, effectiveness of technical support.

Baize Medical (02609.HK) became a hot Hong Kong stock due to management changes and hitting a 52-week low, but overall market sentiment is negative. Investors need to pay attention to risks such as the company’s loss situation, high valuation, and institutional selling, while noting potential strategic adjustment opportunities brought by the new management. This report provides objective analysis and does not constitute investment advice.